Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

4.020 +0.040 (+1.01%)
Streaming Delayed Price Updated: 11:28 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
What This MannKind Filing Reveals About Three Years of Underperformance ↗
Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗
This disposition was tied to vesting of performance-based RSUs at 83% of the target. 
Via The Motley Fool
Topics Regulatory Compliance
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress ↗
Via Chartmill
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 ↗
Via Chartmill
News headline image
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗
Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗
Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
From MannKind
Via GlobeNewswire
News headline image
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
From MannKind
Via GlobeNewswire
News headline image
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into... 
Via MarketBeat
News headline image
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q1 2026 Earnings Transcript ↗
MannKind (MNKD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
What's Going On With MannKind Stock Friday? ↗
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations. 
Via Benzinga
News headline image
Why MannKind Stock Tumbled on Thursday ↗
Mr. Market was hoping for a better fourth quarter than the company delivered. 
Via The Motley Fool
News headline image
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.” 
Via Stocktwits
Here are the top movers in Wednesday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.